01806nas a2200241   4500000000100000008004100001653001400042653001600056653003000072653001500102653002400117653001900141653001100160100001500171700001400186700001500200700001300215245010700228856005100335300001000386490000700396520116100403       2014                            d10aTreatment10aThalidomide10aStrongyloides stercoralis10aPrednisone10alepromatous leprosy10aHansen disease10aBrazil1 aDe Souza J1 aMachado P1 aTeixeira M1 aSoares N00aRecurrence of Strongyloides stercoralis infection in a patient with Hansen’s disease: A case report.  uhttps://leprosyreview.org/article/85/1/00-1872  a58-620 v853 a<p>In patients with immunosuppressive disorders, S. stercoralis infection may develop into a hyperinfection syndrome which, on rare occasions, may be a life-threatening condition. Therapy of S . stercoralis infection with thiabendazole has been limited, due to its numerous side effects, and has been replaced by albendazole and ivermectin. The present case report describes a case of Strongyloides Hyperinfection Syndrome (SHS) in a patient with Hansen’s disease and lack of response to first-line anthelmintic treatment. A 38 year-old man was diagnosed as having borderline lepromatous leprosy. He developed Erythema Nodosum Leprosum and was treated with thalidomide and prednisone. In May 2010 he was diagnosed with S. stercoralis infection and was treated with albendazole. One year later, the stool examination showed continued presence of S. stercoralis larvae. He was treated with ivermectin (6 mg) in a double dose (given 1 month apart) which resulted in larvae excretion clearance. The absence of infection was confirmed three times during a 1 year follow-up period by stool examination and non-detection of anti-S. stercoralis IgG levels.</p>